Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug metformin could help heal spinal cord injuries

NCT ID NCT07272967

Disease control Sponsor: Badr University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether metformin, a common diabetes medicine, can help people recover after a spinal cord injury. The drug may reduce scar tissue that blocks nerve healing. Researchers will give metformin or a placebo to 34 adults with recent thoraco-lumbar spinal cord injury and measure their neurological recovery and pain levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin (Glucophage) 1000 mg tablets
What this could lead to
If it works, this could point toward a new, safe way to improve nerve recovery and reduce pain after spinal cord injury.
What could go wrong
This is a small early-phase trial with only 34 participants, so results may not apply widely. Metformin's effect on spinal cord injury is still unproven in humans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years, who had acute, non-penetrating thoraco-lumbar SCI (T1-conus medullaris), with new neurological deficits. * Injury occurred within the past 24 hours before enrollment. * American Spinal Injury Association (ASIA) Impairment Scale grade B-D. * Able to undergo MRI of the spine. * Informed consent provided by patient or legal representative. Exclusion Criteria: * Major spinal transaction or cervical spinal cord injury. * Prior spinal surgery or pre-existing spinal pathology (e.g., kyphosis, tumors). * Concomitant severe traumatic brain injury (Glasgow Coma Scale \< 13) or other CNS injury that would confound neurological assessment. * Known diabetes mellitus (type 1 or 2) or current use of metformin. * Penetrating spinal injury (e.g. gunshot, stab wound). * Implanted metallic devices or conditions precluding MRI. * Pregnancy or breastfeeding. * Severe comorbidities (e.g. end-stage liver disease, renal failure with eGFR\<30 mL/min). * Known allergy to metformin. * Uncontrolled infection or sepsis at presentation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury(SCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gliosis spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal cord injury(SCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Neurosurgery department at Menoufia University hospitals at Menoufia University.

    Shibīn al Kawm, Menoufia, 32817, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.